comparemela.com

Latest Breaking News On - Kashiv specialty pharmaceuticals - Page 1 : comparemela.com

Amneal Reports First Quarter 2024 Financial Results

‒ Q1 2024 Net Revenue of $659 million; GAAP Net Loss of $92 million; Diluted Loss per Share of $0.30 ‒ ‒ Adjusted EBITDA of $152 million; Adjusted Diluted EPS of $0.14 ‒ ‒ Company has.

United-states
American
America
Chintu-patel
Amneal-pharmaceuticals-inc
Kashiv-specialty-pharmaceuticals
Exchange-commission
Amneal-group
Drug-administration
Nasdaq
Saol-international
Amneal-pharmaceuticals

Amneal Reports Fourth Quarter and Full Year 2023 Financial Results

Amneal Reports Fourth Quarter and Full Year 2023 Financial Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states
America
Chintu-patel
Anthony-dimeo
Saol-international
Drug-administration
Amneal-group
Amneal-pharmaceuticals-inc
Exchange-commission
Kashiv-specialty-pharmaceuticals
Nasdaq
Full-year

Amneal Reports Second Quarter 2023 Financial Results

‒ Q2 2023 Net Revenue of $599 million; GAAP Net Income of $12 million; Diluted EPS of $0.08 ‒ ‒ Q2 2023 Adjusted Net Income of $57 million; Adjusted EBITDA of $146 million; Adjusted Diluted.

United-states
America
Chintu-patel
Saol-international
Drug-administration
Amneal-group
Kashiv-specialty-pharmaceuticals
Exchange-commission
Amneal-pharmaceuticals-inc
Amneal-pharmaceuticals
Co-chief-executive
Full-year

vimarsana © 2020. All Rights Reserved.